Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

nufacturing and marketing FavId or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of FavId and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations, including the conditions to the Company's ability to access the committed equity financing facility and therefore fund operations through the first half of 2008; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... , , , , ... of purifying amplicons as small as 100bp. AMPure yields high quality PCR , ... or filtration steps. The protocol can be easily automated or performed , ... , EFFICIENT PCR PURIFICATION ...
... , , , , Here are some troubleshooting hints that we have gathered , ... , , , , ... <a , href="#Option4">Primer annealing temperature is too low ... , , ...
... , , , , , , ... PCR primers , that are specific for that mRNA sequence. The ... of cDNA and an amplified , product derived from contaminating genomic ... (see figure below). , , , , , ...
Cached Biology Technology:AMPURE PURIFICATION SYSTEM 2AMPURE PURIFICATION SYSTEM 3Trouble-shooting: Smeared bands 2Trouble-shooting: Smeared bands 3Trouble-shooting: Smeared bands 4Trouble-shooting: Smeared bands 5
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... variety of canary seeds bred specifically for human consumption qualifies ... with celiac disease (CD), scientists have confirmed in a study ... . Joyce Irene Boye and colleagues point out ... alone have CD. They develop gastrointestinal and other symptoms from ...
... A Cornell University study offers further proof that the divergence ... years ago was profoundly influenced by mutations to DNA sequences ... The study, published June 9 in Nature Genetics , ... must play an important role in evolution since there is ...
... June 19, 2013 Elsevier, a world-leading provider of scientific, ... announce the launch of a new open access journal, ... , Elsevier,s earth and planetary science journals portfolio has its ... a forum for rapid publication of top research within the ...
Cached Biology News:New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
Functionally tested for consistent G-banding of chromosomes....
... optimized for serum-free growth of Ready-Plaque Sf9 ... medium, Sf9 cultures routinely reach densities greater ... above 95%. This medium is also recommended ... staining of pBACgus recombinants develops faster than ...
... is formuatled for the growth of ... Sf21 cells. Grace's Insect Mediu, Unsupplemented ... does not contain lactalbumin hydrosylate, and ... Grace's Insect Medium, Supplemented is formulated ...
TNM-FH Insect Medium 1 liter...
Biology Products: